Cardiac failure is a devastating condition leading to a high mortality rate and a troubling economic burden. Over the past 40 years, the concept and treatment for cardiac failure have continued evolving. Conceptually, cardiac failure has been transformed from a volume disease related to renal hemostasis, a hemodynamic disease, to a neurohormonal disease. Along with these changes in our basic understanding about cardiac failure, new treatments have improved the survival of those suffering from cardiac failure. Nevertheless, the mortality rate for a patient with heart failure is still around 10% for the first year with the modern treatment.

Our past credits in the field of cardiac failure management have introduced many opportunities of clinical trials internationally. With our own path in the clinical trials of cardiac failure, we witness the changes of this fast-moving field. Furthermore, we would like to shed our lights on other centers that have an aim to advance cardiac failure knowledge.

Global achievement and industry collaboration

• To better organize clinical trial activities across major hospitals in the field of heart failure
• To conduct clinical trials at the best quality

Economic aspect

• To facilitate the market approval of vericiguat (NCT02861534) and dapagliflozin (NCT03036124)

Social impact

• To chair the writing committee of the 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes